Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of patupilone compared to
pegylated liposomal doxorubicin. Additionally, this study will assess the ability of
patupilone to extend the survival time and potential beneficial effects in women who have
nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Doxorubicin Epothilone B Epothilones Liposomal doxorubicin Taxane